Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule

Gijs G Zom; Dmitri V Filippov; Gijsbert A van der Marel; Hermen S Overkleeft; Cornelis J Melief; Ferry Ossendorp

doi:10.4161/21624011.2014.947892

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule

Oncoimmunology. 2014 Jul 3;3(7):e947892. doi: 10.4161/21624011.2014.947892. eCollection 2014.

Authors

Gijs G Zom¹, Dmitri V Filippov², Gijsbert A van der Marel², Hermen S Overkleeft², Cornelis J Melief³, Ferry Ossendorp¹

Affiliations

¹ Department of Immunohematology and Blood Transfusion; Leiden University Medical Center ; Leiden, The Netherlands.
² Leiden Institute of Chemistry; University of Leiden ; Leiden, The Netherlands.
³ ISA Pharmaceuticals ; Leiden, The Netherlands.

Abstract

Aiming to increase the potency of synthetic long peptide (SLP)-based cancer vaccines, the Toll-like receptor 2 (TLR2) ligand Pam₃CSK₄ was conjugated in a chemically defined fashion to SLPs harbouring both cytotoxic T lymphocyte (CTL) and T helper epitopes. We recently showed that these SLP-conjugates induce strong antitumor immunity in murine cancer models.

Keywords: SLP; TLR2; Toll-like receptor; Tumor; conjugate; immunotherapy; lymphoma; melanoma; synthetic long peptides; vaccination.

Publication types

Research Support, Non-U.S. Gov't

Grants and funding

This work has been funded by Netherlands Organization for Scientific Research (NWO) as a part of the ‘From Molecule to Cell’ program (to DVF, GAM, and FO), a Dr Mildred Scheel-Grant from the Deutsche Krebshilfe (CMB), and the framework of project D1-101 within of the Dutch Top Institute Pharma (to CM, FO, HO and SK) and a Dutch Cancer Society (KWF) grant (GGZ).